Kissei Pharmaceutical Co., Ltd. (KSPHF)

Market Cap	1.07B -16.0%
Revenue (ttm)	606.63M +10.3%
Net Income	86.03M +13.0%
EPS	2.08 +17.3%
Shares Out	n/a
PE Ratio	12.44
Forward PE	n/a
Dividend	1.29 (5.00%)
Ex-Dividend Date	Sep 29, 2026

Volume	121
Open	25.77
Previous Close	26.97
Day's Range	25.77 - 25.77
52-Week Range	23.23 - 31.90
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2026

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 1,786
• Stock Exchange: OTCMKTS
• Ticker Symbol: KSPHF

Financial Performance

In fiscal year 2026, Kissei Pharmaceutical's revenue was 97.41 billion, an increase of 10.28% compared to the previous year's 88.33 billion. Earnings were 13.78 billion, an increase of 15.20%.

Financial numbers in JPY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 9, 2026

Data Sources Report a data error